CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing. With the expansion of its international operations, product development, and sales in significant international markets, Deepak’s appointment supports the Company’s next stage of commercial development.
Deepak’s appointment, which comes after that of Dr. Paul Brooks as CEO in December 20221, will help to advance CN Bio’s international scale-up operations for both the product and service sides of the business. Deepak has more than 30 years of commercial experience in the life sciences sector. This includes aiding in the recently launched PhysioMimix® Single-organ Higher-Throughput (HT) System2 by the Company, which was created to get around adoption obstacles that are currently preventing the use of predictive human liver models.
In addition to supporting the expansion of current products and services into the drug discovery, bioproduction, research, and diagnostics markets, Deepak has provided leadership for high-performance sales and marketing teams to establish new technologies, from commercialization through to global scale-up. He previously served as the Head of Global Commercial at PerkinElmer’s Horizon Discovery before joining CN Bio. an an a…………….. Additionally, he worked for Affymetrix and Applied Biosystems’ Genetic Analysis Unit in senior sales and marketing roles (formerly a PerkinElmer company). Deepak graduated from the Polytechnic of Central London with a BSc in biotechnology.
Having had extensive experience within the life science industry, I am excited by the possibilities of OOC technology, and how fast the potential of this technology is being realised. As evidenced by the recent FDA Modernization Act 2.0 legislation in the US, this is a very promising time for the technology, and I am looking forward to joining the CN Bio team to bring their cutting-edge systems to more researchers across the globe, to enable decision-making within drug discovery workflows to be made with more confidence and earlier than ever before.”
